Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference
Vaxcyte, formerly SutroVax, announced participation in a fireside chat at the Evercore ISI 3rd Annual HealthCONx conference on December 2, 2020, at 1:50 PM ET. The event aims to discuss the company’s innovative vaccine developments targeting widespread infectious diseases. A live webcast will be available on the company’s website, with a replay offered for 30 days post-event. Vaxcyte is advancing several candidates, including VAX-24, a preclinical 24-valent pneumococcal conjugate vaccine designed to prevent invasive pneumococcal disease.
- None.
- None.
FOSTER CITY, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that company management will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx conference on Wednesday, December 2, 2020 at 1:50pm ET.
A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.
About Vaxcyte
Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCF™ platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. Vaxcyte’s lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of at least 30 strains, including newly emerging strains responsible for IPD and antibiotic resistance; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease by targeting the keystone pathogen responsible for this chronic, oral inflammatory disease. For more information, visit www.vaxcyte.com.
Contact:
Andrew Guggenhime, Chief Financial Officer & Chief Business Officer
Vaxcyte, Inc.
650-837-0111
investors@vaxcyte.com
FAQ
What is Vaxcyte doing at the Evercore ISI 3rd Annual HealthCONx conference?
When is Vaxcyte's fireside chat scheduled?
How can I watch Vaxcyte's fireside chat?
What is Vaxcyte's lead vaccine candidate?
What diseases are Vaxcyte's vaccines targeting?
